Literature DB >> 24679905

1,5-Anhydro-D-glucitol predicts coronary artery disease prevalence and complexity.

Nobutaka Ikeda1, Hisao Hara2, Yukio Hiroi2.   

Abstract

BACKGROUND: The relationship between hemoglobin A1c (HbA1c) levels and coronary artery disease (CAD) has previously been confirmed. Serum 1,5-anhydro-D-glucitol (1,5-AG) levels are a useful clinical marker for short-term glycemic status that reflect glycemic excursions with greater sensitivity compared with HbA1c, specifically in the postprandial state. Postprandial hyperglycemia is an important CAD risk factor. Thus, the aim of this study was to compare HbA1c with 1,5-AG as a CAD predictor.
METHODS: The subjects consisted of 336 consecutive patients who underwent their first coronary angiography between July 2011 and March 2013. The relationship between CAD prevalence and HbA1c as well as CAD prevalence and 1,5-AG levels was evaluated. The correlation between CAD complexity and HbA1c or 1,5-AG was also assessed. CAD complexity was evaluated by the SYNTAX score.
RESULTS: CAD patients presented with significantly lower 1,5-AG and higher HbA1c values than patients without CAD (11.6 μg/ml [6.1, 19.1] vs. 17.6 μg/ml [11.9, 25.0], p<0.001, and 6.0% [5.6, 7.1] vs. 5.7% [5.4, 6.2], p<0.001, respectively) (median [25th, 75th percentiles]). According to logistic regression analysis, 1,5-AG was a predictor of CAD prevalence (odds ratio 0.94, 95% confidence interval 0.90-0.97). However, HbA1c levels did not present a predictive value for CAD. Levels of 1,5-AG and HbA1c were significantly correlated with SYNTAX scores (ρ=-0.27, p<0.001; and ρ=0.23, p<0.001, respectively).
CONCLUSIONS: The use of 1,5-AG, may be superior to HbA1c in predicting CAD prevalence. Both 1,5-AG and HbA1c correlate with CAD complexity.
Copyright © 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  1,5-Anhydro-d-glucitol; Coronary artery disease; Hemoglobin A1c; SYNTAX score

Mesh:

Substances:

Year:  2014        PMID: 24679905     DOI: 10.1016/j.jjcc.2014.02.014

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  10 in total

1.  1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: results from non-targeted metabolomics.

Authors:  Gesiane Tavares; Gabriela Venturini; Kallyandra Padilha; Roberto Zatz; Alexandre C Pereira; Ravi I Thadhani; Eugene P Rhee; Silvia M O Titan
Journal:  Metabolomics       Date:  2018-02-27       Impact factor: 4.290

2.  Lower 1,5-anhydroglucitol is associated with adverse clinical events after percutaneous coronary intervention.

Authors:  Takayuki Fujiwara; Masashi Yoshida; Naoyuki Akashi; Hodaka Yamada; Takunori Tsukui; Tomohiro Nakamura; Kenichi Sakakura; Hiroshi Wada; Kenshiro Arao; Takuji Katayama; Tomio Umemoto; Hiroshi Funayama; Yoshitaka Sugawara; Takeshi Mitsuhashi; Masafumi Kakei; Shin-Ichi Momomura; Junya Ako
Journal:  Heart Vessels       Date:  2015-04-29       Impact factor: 2.037

Review 3.  Cardiovascular disease and 1,5-anhydro-d-glucitol.

Authors:  Nobutaka Ikeda; Yukio Hiroi
Journal:  Glob Health Med       Date:  2019-12-31

4.  Glycated albumin is more closely correlated with coronary artery disease than 1,5-anhydroglucitol and glycated hemoglobin A1c.

Authors:  Xiaojing Ma; Xiang Hu; Jian Zhou; Yaping Hao; Yuqi Luo; Zhigang Lu; Yuqian Bao; Weiping Jia
Journal:  Cardiovasc Diabetol       Date:  2015-02-07       Impact factor: 9.951

5.  Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention.

Authors:  Shuhei Takahashi; Kazunori Shimada; Katsumi Miyauchi; Tetsuro Miyazaki; Eiryu Sai; Manabu Ogita; Shuta Tsuboi; Hiroshi Tamura; Shinya Okazaki; Tomoyuki Shiozawa; Shohei Ouchi; Tatsuro Aikawa; Tomoyasu Kadoguchi; Hamad Al Shahi; Takuma Yoshihara; Makoto Hiki; Kikuo Isoda; Hiroyuki Daida
Journal:  Cardiovasc Diabetol       Date:  2016-10-11       Impact factor: 9.951

6.  Impact of serum 1,5-anhydro-D-glucitol level on the prediction of severe coronary artery calcification: an intravascular ultrasound study.

Authors:  Hideki Wada; Tomotaka Dohi; Katsumi Miyauchi; Norihito Takahashi; Hirohisa Endo; Yoshiteru Kato; Manabu Ogita; Iwao Okai; Hiroshi Iwata; Shinya Okazaki; Kikuo Isoda; Kazunori Shimada; Satoru Suwa; Hiroyuki Daida
Journal:  Cardiovasc Diabetol       Date:  2019-06-03       Impact factor: 9.951

7.  Effect of 1,5-anhydroglucitol levels on culprit plaque rupture in diabetic patients with acute coronary syndrome.

Authors:  Gong Su; Ming-Xi Gao; Gen-Ling Shi; Xi-Xi Dai; Wei-Feng Yao; Tao Zhang; Shao-Wei Zhuang
Journal:  Cardiovasc Diabetol       Date:  2020-05-30       Impact factor: 9.951

Review 8.  Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation.

Authors:  Andreas S Papazoglou; Anastasios Kartas; Dimitrios V Moysidis; Christos Tsagkaris; Stavros P Papadakos; Alexandra Bekiaridou; Athanasios Samaras; Efstratios Karagiannidis; Marios Papadakis; George Giannakoulas
Journal:  Cardiovasc Diabetol       Date:  2022-03-14       Impact factor: 9.951

9.  The clinical impact of serum 1,5-anhydro-D-glucitol levels on coronary artery calcification and adverse outcomes assessed by coronary optical coherence tomography in diabetic patients.

Authors:  Hsin-I Teng; Hsiang-Yao Chen; Chuan-Tsai Tsai; Wei-Chieh Huang; Ying-Ying Chen; Chien-Hung Hsueh; William K Hau; Tse-Min Lu
Journal:  Front Cardiovasc Med       Date:  2022-08-30

10.  Low 1,5-anhydroglucitol levels are associated with long-term cardiac mortality in acute coronary syndrome patients with hemoglobin A1c levels less than 7.0.

Authors:  Shohei Ouchi; Kazunori Shimada; Tetsuro Miyazaki; Shuhei Takahashi; Yurina Sugita; Megumi Shimizu; Azusa Murata; Tomoyasu Kadoguchi; Takao Kato; Tatsuro Aikawa; Shoko Suda; Eiryu Sai; Masaru Hiki; Hiroshi Iwata; Takatoshi Kasai; Katsumi Miyauchi; Hiroyuki Daida
Journal:  Cardiovasc Diabetol       Date:  2017-11-21       Impact factor: 9.951

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.